Cryo-Cell International Inc (CCEL) FinancialsCCELCryo-Cell International Inc

Cryo-Cell International Inc (CCEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Processing and storage fees, accounting for 99.5% of total sales, equivalent to $7.64M. Other significant revenue streams include Product revenue and Public banking revenue. Understanding this composition is critical for investors evaluating how CCEL navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Cryo-Cell International Inc maintains a gross margin of 76.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.40%, while the net margin is 7.13%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CCEL converts its operational activities into shareholder value.

In the context of the broader market, CCEL competes directly with industry leaders such as SWVL and BTOC. With a market capitalization of $31.93M, it holds a significant position in the sector. When comparing efficiency, CCEL's gross margin of 76.07% stands against SWVL's 21.48% and BTOC's -4.48%. Such benchmarking helps identify whether Cryo-Cell International Inc is trading at a premium or discount relative to its financial performance.

Cryo-Cell International has shown fluctuating financial performance, with total revenue decreasing by 3.6% year-over-year in Q1 2026, and a net income drop to $47,000 from $283,000 in the same quarter last year. The gross margin remains strong at 76.07%, but the company faces challenges in maintaining profitability.